Which has higher valuation & earnings, ESLA or AKTX?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Estrella Immunopharma N/A N/A -$13.06M -$0.34 N/A Akari Therapeutics N/A N/A -$17.30M N/A N/A

Is ESLA or AKTX more profitable?

Estrella Immunopharma's return on equity of 0.00% beat Akari Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Estrella Immunopharma N/A N/A -397.36% Akari Therapeutics N/A -123.29% -63.01%

Does the media favor ESLA or AKTX?

In the previous week, Estrella Immunopharma and Estrella Immunopharma both had 1 articles in the media. Estrella Immunopharma's average media sentiment score of 0.00 equaled Akari Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Estrella Immunopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Akari Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, RNXT or AKTX?

RenovoRx has higher revenue and earnings than Akari Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio RenovoRx $1.12M 36.20 -$11.17M -$0.33 N/A Akari Therapeutics N/A N/A -$17.30M N/A N/A

Does the media favor RNXT or AKTX?

In the previous week, RenovoRx and RenovoRx both had 1 articles in the media. RenovoRx's average media sentiment score of 0.92 beat Akari Therapeutics' score of 0.00 indicating that RenovoRx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RenovoRx 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Akari Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, ATHE or AKTX?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alterity Therapeutics N/A N/A -$7.87M N/A N/A Akari Therapeutics N/A N/A -$17.30M N/A N/A

Is ATHE or AKTX more profitable?

Alterity Therapeutics' return on equity of 0.00% beat Akari Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Alterity Therapeutics N/A N/A N/A Akari Therapeutics N/A -123.29% -63.01%

Does the media favor ATHE or AKTX?

In the previous week, Alterity Therapeutics had 2 more articles in the media than Akari Therapeutics. MarketBeat recorded 3 mentions for Alterity Therapeutics and 1 mentions for Akari Therapeutics. Akari Therapeutics' average media sentiment score of 0.00 beat Alterity Therapeutics' score of -0.26 indicating that Akari Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alterity Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Akari Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, AKTX or IXHL?

Akari Therapeutics has higher earnings, but lower revenue than Incannex Healthcare. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Akari Therapeutics N/A N/A -$17.30M N/A N/A Incannex Healthcare $90K 449.54 -$46.88M -$1.55 N/A

Is AKTX or IXHL more profitable?

Incannex Healthcare's return on equity of -81.01% beat Akari Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Akari Therapeutics N/A -123.29% -63.01% Incannex Healthcare N/A -81.01% -76.11%

Which has better earnings and valuation, BTAI or AKTX?

Akari Therapeutics has lower revenue, but higher earnings than BioXcel Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioXcel Therapeutics $640K 38.71 -$69.90M -$5.75 N/A Akari Therapeutics N/A N/A -$17.30M N/A N/A

Does the media prefer BTAI or AKTX?

In the previous week, BioXcel Therapeutics and BioXcel Therapeutics both had 1 articles in the media. BioXcel Therapeutics' average media sentiment score of 0.67 beat Akari Therapeutics' score of 0.00 indicating that BioXcel Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioXcel Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Akari Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Akari Therapeutics (AKTX) Competitors

$14.21 -1.27 (-8.20%)

Closing price 07/8/2026 04:00 PM Eastern

Extended Trading

$14.48 +0.26 (+1.86%)

As of 07/8/2026 06:07 PM Eastern

Compare

AKTX vs. ESLA, RNXT, ATHE, IXHL, and BTAI

Should you buy Akari Therapeutics stock or one of its competitors? MarketBeat compares Akari Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Akari Therapeutics include Estrella Immunopharma (ESLA), RenovoRx (RNXT), Alterity Therapeutics (ATHE), Incannex Healthcare (IXHL), and BioXcel Therapeutics (BTAI). These companies are all part of the "pharmaceutical products" industry.

How does Akari Therapeutics compare to Estrella Immunopharma?

Estrella Immunopharma (NASDAQ:ESLA) and Akari Therapeutics (NASDAQ:AKTX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, institutional ownership, risk, profitability and earnings.

In the previous week, Estrella Immunopharma and Estrella Immunopharma both had 1 articles in the media. Estrella Immunopharma's average media sentiment score of 0.00 equaled Akari Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Estrella Immunopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Akari Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Estrella Immunopharma's return on equity of 0.00% beat Akari Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Estrella Immunopharma	N/A	N/A	-397.36%
Akari Therapeutics	N/A	-123.29%	-63.01%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Estrella Immunopharma	N/A	N/A	-$13.06M	-$0.34	N/A
Akari Therapeutics	N/A	N/A	-$17.30M	N/A	N/A

0.4% of Estrella Immunopharma shares are owned by institutional investors. Comparatively, 5.1% of Akari Therapeutics shares are owned by institutional investors. 5.8% of Estrella Immunopharma shares are owned by insiders. Comparatively, 32.2% of Akari Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Estrella Immunopharma currently has a consensus price target of $8.00, indicating a potential upside of 788.99%. Akari Therapeutics has a consensus price target of $89.00, indicating a potential upside of 526.32%. Given Estrella Immunopharma's higher probable upside, analysts clearly believe Estrella Immunopharma is more favorable than Akari Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Estrella Immunopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Akari Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Estrella Immunopharma has a beta of 0.85, indicating that its stock price is 15% less volatile than the broader market. Comparatively, Akari Therapeutics has a beta of 1.38, indicating that its stock price is 38% more volatile than the broader market.

Summary

Akari Therapeutics beats Estrella Immunopharma on 6 of the 9 factors compared between the two stocks.

How does Akari Therapeutics compare to RenovoRx?

RenovoRx (NASDAQ:RNXT) and Akari Therapeutics (NASDAQ:AKTX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends, earnings and media sentiment.

RenovoRx has a beta of 0.99, indicating that its share price is 1% less volatile than the broader market. Comparatively, Akari Therapeutics has a beta of 1.38, indicating that its share price is 38% more volatile than the broader market.

RenovoRx has higher revenue and earnings than Akari Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RenovoRx	$1.12M	36.20	-$11.17M	-$0.33	N/A
Akari Therapeutics	N/A	N/A	-$17.30M	N/A	N/A

In the previous week, RenovoRx and RenovoRx both had 1 articles in the media. RenovoRx's average media sentiment score of 0.92 beat Akari Therapeutics' score of 0.00 indicating that RenovoRx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RenovoRx	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Akari Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Akari Therapeutics has a net margin of 0.00% compared to RenovoRx's net margin of -823.98%. Akari Therapeutics' return on equity of -123.29% beat RenovoRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RenovoRx	-823.98%	-135.03%	-101.92%
Akari Therapeutics	N/A	-123.29%	-63.01%

3.1% of RenovoRx shares are owned by institutional investors. Comparatively, 5.1% of Akari Therapeutics shares are owned by institutional investors. 9.4% of RenovoRx shares are owned by company insiders. Comparatively, 32.2% of Akari Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

RenovoRx presently has a consensus target price of $8.50, indicating a potential upside of 844.44%. Akari Therapeutics has a consensus target price of $89.00, indicating a potential upside of 526.32%. Given RenovoRx's stronger consensus rating and higher probable upside, equities analysts plainly believe RenovoRx is more favorable than Akari Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RenovoRx	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Akari Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

RenovoRx and Akari Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Akari Therapeutics compare to Alterity Therapeutics?

Alterity Therapeutics (NASDAQ:ATHE) and Akari Therapeutics (NASDAQ:AKTX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends, earnings and media sentiment.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alterity Therapeutics	N/A	N/A	-$7.87M	N/A	N/A
Akari Therapeutics	N/A	N/A	-$17.30M	N/A	N/A

Alterity Therapeutics has a beta of 0.25, indicating that its share price is 75% less volatile than the broader market. Comparatively, Akari Therapeutics has a beta of 1.38, indicating that its share price is 38% more volatile than the broader market.

In the previous week, Alterity Therapeutics had 2 more articles in the media than Akari Therapeutics. MarketBeat recorded 3 mentions for Alterity Therapeutics and 1 mentions for Akari Therapeutics. Akari Therapeutics' average media sentiment score of 0.00 beat Alterity Therapeutics' score of -0.26 indicating that Akari Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alterity Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Akari Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

2.1% of Alterity Therapeutics shares are owned by institutional investors. Comparatively, 5.1% of Akari Therapeutics shares are owned by institutional investors. 38.8% of Alterity Therapeutics shares are owned by company insiders. Comparatively, 32.2% of Akari Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Alterity Therapeutics' return on equity of 0.00% beat Akari Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alterity Therapeutics	N/A	N/A	N/A
Akari Therapeutics	N/A	-123.29%	-63.01%

Alterity Therapeutics presently has a consensus target price of $13.00, indicating a potential upside of 132.97%. Akari Therapeutics has a consensus target price of $89.00, indicating a potential upside of 526.32%. Given Akari Therapeutics' higher probable upside, analysts plainly believe Akari Therapeutics is more favorable than Alterity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alterity Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Akari Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Alterity Therapeutics beats Akari Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Akari Therapeutics compare to Incannex Healthcare?

Akari Therapeutics (NASDAQ:AKTX) and Incannex Healthcare (NASDAQ:IXHL) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk.

Akari Therapeutics has a beta of 1.38, indicating that its share price is 38% more volatile than the broader market. Comparatively, Incannex Healthcare has a beta of 6.95, indicating that its share price is 595% more volatile than the broader market.

Akari Therapeutics currently has a consensus target price of $89.00, suggesting a potential upside of 526.32%. Incannex Healthcare has a consensus target price of $18.00, suggesting a potential upside of 432.54%. Given Akari Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Akari Therapeutics is more favorable than Incannex Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akari Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Incannex Healthcare	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

5.1% of Akari Therapeutics shares are held by institutional investors. Comparatively, 0.4% of Incannex Healthcare shares are held by institutional investors. 32.2% of Akari Therapeutics shares are held by insiders. Comparatively, 1.3% of Incannex Healthcare shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Akari Therapeutics had 1 more articles in the media than Incannex Healthcare. MarketBeat recorded 1 mentions for Akari Therapeutics and 0 mentions for Incannex Healthcare. Akari Therapeutics' average media sentiment score of 0.00 equaled Incannex Healthcare'saverage media sentiment score.

Company	Overall Sentiment
Akari Therapeutics	Neutral
Incannex Healthcare	Neutral

Akari Therapeutics has higher earnings, but lower revenue than Incannex Healthcare.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akari Therapeutics	N/A	N/A	-$17.30M	N/A	N/A
Incannex Healthcare	$90K	449.54	-$46.88M	-$1.55	N/A

Incannex Healthcare's return on equity of -81.01% beat Akari Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Akari Therapeutics	N/A	-123.29%	-63.01%
Incannex Healthcare	N/A	-81.01%	-76.11%

Summary

Akari Therapeutics beats Incannex Healthcare on 8 of the 11 factors compared between the two stocks.

How does Akari Therapeutics compare to BioXcel Therapeutics?

BioXcel Therapeutics (NASDAQ:BTAI) and Akari Therapeutics (NASDAQ:AKTX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, dividends, risk, profitability, earnings and media sentiment.

BioXcel Therapeutics has a beta of 0.27, meaning that its share price is 73% less volatile than the broader market. Comparatively, Akari Therapeutics has a beta of 1.38, meaning that its share price is 38% more volatile than the broader market.

BioXcel Therapeutics currently has a consensus price target of $11.00, suggesting a potential upside of 1,271.23%. Akari Therapeutics has a consensus price target of $89.00, suggesting a potential upside of 526.32%. Given BioXcel Therapeutics' higher possible upside, equities analysts plainly believe BioXcel Therapeutics is more favorable than Akari Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioXcel Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Akari Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

30.7% of BioXcel Therapeutics shares are owned by institutional investors. Comparatively, 5.1% of Akari Therapeutics shares are owned by institutional investors. 3.7% of BioXcel Therapeutics shares are owned by insiders. Comparatively, 32.2% of Akari Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, BioXcel Therapeutics and BioXcel Therapeutics both had 1 articles in the media. BioXcel Therapeutics' average media sentiment score of 0.67 beat Akari Therapeutics' score of 0.00 indicating that BioXcel Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioXcel Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Akari Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Akari Therapeutics has lower revenue, but higher earnings than BioXcel Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioXcel Therapeutics	$640K	38.71	-$69.90M	-$5.75	N/A
Akari Therapeutics	N/A	N/A	-$17.30M	N/A	N/A

Akari Therapeutics has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -11,078.53%. BioXcel Therapeutics' return on equity of 0.00% beat Akari Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioXcel Therapeutics	-11,078.53%	N/A	-201.53%
Akari Therapeutics	N/A	-123.29%	-63.01%

Summary

BioXcel Therapeutics and Akari Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.

Get Akari Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AKTX vs. The Competition

Export

Metric	Akari Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$17.72M	$3.80B	$6.99B	$12.46B
Dividend Yield	N/A	2.17%	2.67%	7.39%
P/E Ratio	N/A	21.49	27.17	24.24
Price / Sales	N/A	328.43	534.05	96.53
Price / Cash	N/A	148.60	49.24	56.96
Price / Book	0.57	8.47	10.83	6.38
Net Income	-$17.30M	$23.73M	$3.56B	$331.19M
7 Day Performance	36.50%	0.14%	0.00%	-1.32%
1 Month Performance	-5.27%	11.27%	5.29%	1.27%
1 Year Performance	-68.46%	55.65%	30.32%	20.73%

Akari Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AKTX Akari Therapeutics	2.1331 of 5 stars	$14.21 -8.2%	$89.00 +526.3%	-68.3%	$17.72M	N/A	N/A	9	News Coverage Analyst Upgrade Gap Down
ESLA Estrella Immunopharma	1.6575 of 5 stars	$1.00 -2.7%	$8.00 +698.4%	+3.3%	$44.33M	N/A	N/A	N/A	News Coverage Positive News Gap Down
RNXT RenovoRx	4.3266 of 5 stars	$0.98 +1.0%	$8.50 +767.3%	-30.8%	$43.75M	$1.12M	N/A	6	Positive News
ATHE Alterity Therapeutics	2.7814 of 5 stars	$5.37 +9.8%	$13.00 +142.1%	+35.8%	$43.36M	N/A	N/A	10
IXHL Incannex Healthcare	2.1793 of 5 stars	$3.76 +3.9%	$18.00 +378.7%	-48.7%	$43.31M	$90K	N/A	3

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AKTX) was last updated on 7/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Akari Therapeutics (AKTX) Competitors

AKTX vs. ESLA, RNXT, ATHE, IXHL, and BTAI

How does Akari Therapeutics compare to Estrella Immunopharma?

Summary

How does Akari Therapeutics compare to RenovoRx?

Summary

How does Akari Therapeutics compare to Alterity Therapeutics?

Summary

How does Akari Therapeutics compare to Incannex Healthcare?

Summary

How does Akari Therapeutics compare to BioXcel Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKTX vs. The Competition

Akari Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Akari Therapeutics (AKTX) Competitors

AKTX vs. ESLA, RNXT, ATHE, IXHL, and BTAI

How does Akari Therapeutics compare to Estrella Immunopharma?

Does the media favor ESLA or AKTX?

Is ESLA or AKTX more profitable?

Which has higher valuation & earnings, ESLA or AKTX?

Do insiders & institutionals believe in ESLA or AKTX?

Do analysts recommend ESLA or AKTX?

Which has more risk & volatility, ESLA or AKTX?

Summary

How does Akari Therapeutics compare to RenovoRx?

Which has more volatility & risk, RNXT or AKTX?

Which has preferable earnings and valuation, RNXT or AKTX?

Does the media favor RNXT or AKTX?

Is RNXT or AKTX more profitable?

Do institutionals and insiders have more ownership in RNXT or AKTX?

Do analysts recommend RNXT or AKTX?

Summary

How does Akari Therapeutics compare to Alterity Therapeutics?

Which has preferable earnings and valuation, ATHE or AKTX?

Which has more volatility & risk, ATHE or AKTX?

Does the media favor ATHE or AKTX?

Do institutionals and insiders have more ownership in ATHE or AKTX?

Is ATHE or AKTX more profitable?

Do analysts recommend ATHE or AKTX?

Summary

How does Akari Therapeutics compare to Incannex Healthcare?

Which has more volatility & risk, AKTX or IXHL?

Do analysts rate AKTX or IXHL?

Do insiders & institutionals have more ownership in AKTX or IXHL?

Does the media refer more to AKTX or IXHL?

Which has preferable valuation and earnings, AKTX or IXHL?

Is AKTX or IXHL more profitable?

Summary

How does Akari Therapeutics compare to BioXcel Therapeutics?

Which has more volatility & risk, BTAI or AKTX?

Do analysts prefer BTAI or AKTX?

Do insiders and institutionals have more ownership in BTAI or AKTX?

Does the media prefer BTAI or AKTX?

Which has better earnings and valuation, BTAI or AKTX?

Is BTAI or AKTX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKTX vs. The Competition

Akari Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools